NFKB1 and metabolic dysfunction-associated steatohepatitis: EETs, metabolites of the CYP450 pathway, have been shown to reduce liver lipid peroxidation and inflammation in NASH mice through PPARα and NF-κB signaling pathways (14, 15, 27, 39), highlighting their anti-inflammatory potential in various diseases (17–19).